Sotera Health Company (SHC)
NEUTRALFondamental
58
Prix
$19.54
Capitalisation boursière
$5.48B
Partie 1 · Ce que vaut l'entreprise
Vue d'ensemble
Sotera Health Company provides sterilization solutions, lab testing, and advisory services for the healthcare industry in the United States, Canada, Europe, and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. The Sterigenics segment offers outsourced terminal sterilization and irradiation services using gamma irradiation, ethylene oxide processing, and electron beam irradiation technologies for medical devices, pharmaceutical, and food safety and advanced applications markets. The Nordion segment provides Cobalt-60 used in the sterilization and irradiation processes for the medical device, pharmaceutical, food safety, and high-performance materials industries, as well as in the treatment of cancer. It also offers gamma irradiation systems. The Nelson Labs segment provides outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries. The company was formerly known as Sotera Health Topco, Inc. and changed its name to Sotera Health Company in October 2020. Sotera Health Company was incorporated in 2015 and is headquartered in Broadview Heights, Ohio.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Bilan & Liquidités
Chiffre d'affaires
$1.22B
12 derniers mois (au 30/06/2026)
Résultat net
$163M
12 derniers mois (au 30/06/2026)
Flux de trésorerie libre
$149M
Capitaux propres totaux
$606M
Passif total
$2.66B
Ratio de liquidité général
2.80
Couverture des intérêts
-
Dette/EBITDA
3.93
Bénéfice par action
Chiffre d'affaires & Résultat net
Flux de trésorerie libre
Décomposition du résultat
État historique
Marges dans le temps
La dette dans le temps
Le poids de la dette
Grille de la croissance
Croissance — Chiffre d'affaires
Estimation de la juste valeur
Juste valeur
$13.10
Prix actuel
$19.54
Marge de sécurité
-49.1%
Fourchette de juste valeur
$8.52 - $17.69
Méthodes d'estimation
Indicateurs de valorisation
Ratio P/E
33.63
ROE
12.9%
Ratio P/B
8.22
P/FCF
48.54
Marge brute
55.0%
ROIC
-
Radar de rentabilité
Value Creation (Economic Moat)
ROIC
-
WACC
10.4%
ROIC − WACC
-
Critères d'analyse fondamentale
Réussi (13)
- EPS shows upward trend
- Gross Margin 55.0%
- Positive Free Cash Flow
- Current Ratio
- Debt/EBITDA
- Return on Tangible Assets
- ROE 20.6%
- Revenue Growth 5Y 7.3%
- Analyst Consensus 80% Buy
- Earnings Surprise avg 8.4%
- Earnings Quality (OCF/NI) 1.79
- Net Margin Trend 13.4% vs 2.1%
- Piotroski F-Score 6/9
Échoué (9)
- Price CAGR -5.48%
- P/FCF 48.54
- P/B Ratio 8.22
- Debt/Equity ratio
- CapEx intensity
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- Share Dilution 4.0%
Indisponible (5)
- ROIC NaN%
- Dividend Payout NaN%
- Operating Margin NaN%
- Interest Coverage
- PEG Ratio (need PE > 0 and growth > 0)
Score F de Piotroski
Signaux mixtes : certains domaines nécessitent attention
Qualité des bénéfices
Qualité élevée : bénéfices soutenus par la trésorerie
Dilution du capital
Émission de nouvelles actions, diluant la participation
Gouvernance
Équipe dirigeante
| Nom | Titre | Âge |
|---|---|---|
| Mr. Michael B. Petras Jr. | Executive Chairman of the Board | 56 |
| Mr. Jonathan M. Lyons | Senior VP & CFO | 47 |
| Mr. Michael P. Rutz | President of Sterigenics U.S., LLC | 54 |
| Mr. Alton E. Shader | CEO & Director | 52 |
| Mr. Robert G. Hauzie | Chief Information Officer | - |
| Ms. Erika Ostrowski | Senior VP, General Counsel & Corporate Secretary | - |
| Ms. Kristin A. Gibbs | Chief Marketing Officer | - |
| Mr. William O. Lehmann Jr., J.D., M.B.A. | Senior Vice President of Strategy & Corporate Development | 59 |
| Ms. Sally R. Turner | Chief Human Resources Officer | - |
| Ms. Danielle J. Menture | Senior Vice President of Global Environmental, Health & Safety and Sustainability | - |
Risque d'audit
4
Risque du conseil
7
Risque de rémunération
5
Risque droits des actionnaires
7
Partie 2 · Le prix et le moment d'entrer
Cette partie ne dit pas si l'entreprise vaut la peine : elle aide à choisir quand l'acheter, une fois que les fondamentaux vous ont convaincu. À l'intérieur : analyse technique, potentiel, baisses historiques, exposition gamma.
Latest News
Recent headlines for SHC, sourced from Markets Gazette.
- 3/15/2026NEUTRALSotera Health Shares Rise 18% in a Year. Here's What a $37 Million Stake Trim Signals
Sotera Health Company shares have seen an 18% increase over the past year, with recent activity indicating a significant stake trim by an insider amounting to $37 million. Sotera Health provides crucial sterilization and laboratory testing services to highly regulated industries globally, playing a vital role in maintaining essential supply chains. While the stock has performed well, the substantial insider sale could signal a divergence of opinion on future valuation or a need for liquidity, warranting investor attention.
- 3/2/2026NEGATIVESotera Health Up 30% This Past Year, so Why Did One Fund Sell $4 Million in Shares?
Sotera Health, a global provider of sterilization and laboratory solutions to the healthcare, pharmaceutical, and food industries, has seen an impressive 30% growth over the past year. Despite this robust performance, an unidentified fund divested $4 million worth of shares. This move raises questions among investors: why would an institutional entity sell such a significant stake in a rapidly growing company? It could signal strategic profit-taking, a portfolio rebalancing, or potentially a less optimistic view on the company's future prospects not yet apparent to the broader market. Investors should closely monitor upcoming developments and the rationale behind this significant divestment.
- 2/24/2026NEUTRALInsights into Sotera Health Q4 Earnings
Investors are keenly awaiting insights into Sotera Health's fourth-quarter earnings, a pivotal event for assessing the company's performance and future outlook. Analyzing quarterly results is crucial for understanding financial health, revenue growth, and profitability, all of which directly influence market sentiment and investment decisions. While specific details are yet to be disclosed, market focus remains on how Sotera Health navigated operational challenges and opportunities during the period. Key data points, such as revenue, earnings per share (EPS), and future guidance, will be scrutinized to identify trends and potential catalysts for the stock price. Results meeting or exceeding expectations could bolster confidence, whereas a disappointment might trigger a negative reaction.
via Markets Gazette